A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors

Astex Pharmaceuticals, Inc.0 个研究点目标入组 300 人开始时间: 2021年8月4日最近更新: 2021年8月10日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Astex Pharmaceuticals, Inc.
入组人数: 300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1) Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.
•2) Men or women 18 years of age or older.
•3) Subjects with histologically or cytologically confirmed advanced solid tumors that are metastatic or unresectable, who are refractory or have relapsed after treatment with available therapies or for whom standard life-prolonging measures or approved therapies are not available. In Phase 1 Part B and in the Phase 2 portion of the protocol, subjects must also have documented gene alterations in the MAPK pathway as detailed in Section 4.1.2 and Table 2.
•4) In Phase 1 Part B of the protocol, subjects must have disease lesions that are amenable to biopsy.
•5) In the Phase 2 portion of the protocol, subjects must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
•6) Eastern Cooperative Oncology Group performance status 0 to 2.
•7) Acceptable organ function, as evidenced by the following laboratory data:
•a) AST and alanine aminotransferase (ALT) =2×upper limit of normal (ULN) or =3 ULN in
•the presence of liver metastases.
•b) Total serum bilirubin =1.5×ULN.
•c) Absolute neutrophil count (ANC) =1500 cells/mm3 .
•d) Platelet count =100,000 cells/mm3 .
•e) Calculated creatinine clearance (by the standard Cockcroft-Gault formula) of =50 mL/min or glomerular filtration rate of =50 mL/min.
•8) Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]; see protocol for details) must not be pregnant or breastfeeding and must have a negative pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study treatment. Women of child-bearing potential must agree to the following during the treatment period and for 5 half-lives of ASTX029 or metabolite plus 30 days after receipt of the last dose of study treatment:
•a) Refrain from donating eggs (ova, oocytes) for the purpose of reproduction.
•b) Use a contraceptive method that is highly effective with a failure rate of <1% per year, with low user dependency. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk of inclusion of a woman with an early unexpected pregnancy.
•9. Men must agree to the following during the treatment period and for 5 half-lives of ASTX029 or metabolite plus 90 days after receipt of last dose of study treatment:
•a) Refrain from donating sperm.
•b) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and to remain abstinent OR to use a male condom when having sexual intercourse with a woman of childbearing potential (according to recommendations of the CTFG; see protocol for details) who is not currently pregnant, and the female partner should be advised of the benefit of using an additional highly effective contraceptive method with a failure rate of <1% per year as a condom may break or leak. The investigator should evaluate the effectiveness of the contraceptive method before the first dose of study treatment.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 250
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

排除标准

•1) Hypersensitivity to ASTX029 or excipients of the drug product.
•2) Poor medical risk in the investigator’s opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.
•3) Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of study outcomes or interfere with the absorption or metabolism of ASTX029.
•4) Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX029), as follows:
•a) Cytotoxic chemotherapy or radiotherapy within 3 weeks prior. Palliative radiotherapy to a single lesion within 2 weeks prior. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to =Grade 1.
•b) Monoclonal antibodies or biologics within 4 weeks prior. Any encountered treatment related toxicities not stabilized or resolved to =Grade 1.
•c) Molecularly targeted drug or other investigational drugs, without the potential for delayed toxicity, within 4 weeks of the first dose of study treatment or 5 half-lives (minimum
•14 days), whichever is shorter. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to =Grade 1.
•5) Prior treatment with ERK inhibitors.
•6) History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:
•a) Abnormal left ventricular ejection fraction (LVEF; <50%) on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
•b) Congestive cardiac failure of =Grade 3 severity according to New York Heart Association (NYHA) functional classification defined as patients with marked limitation of activity and who are comfortable only at rest.
•c) Unstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
•d) History or evidence of long QT interval corrected for heart rate (QTc), ventricular arrhythmias including ventricular bigeminy, complete left bundle branch block, clinically significant bradyarrhythmias such as sick sinus syndrome, second- and third-degree atrioventricular (AV) block, presence of cardiac pacemaker or defibrillator, or other significant arrhythmias.
•e) Screening 12-lead ECG with measurable QTc interval of =470 msec. (Fridericia's formula should be used to calculate the QTc interval throughout the study.)
•7) Known history of human immunodeficiency virus (HIV) infection or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
•8) Known brain metastases, unless previously treated and stable for at least 3 months with or without steroids.
•9) Known significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the subject to high risk of noncompliance with the protocol treatment or assessments.
•10) History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) including:
•a) Presence of predisposing factors to RVO or CSR (eg, uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus) or
•b) Visible retinal pathology as assessed by ophthalmic examination at screening that is considered a risk factor for RVO or CSR such as:
•Evidence of optic disc cupping or
•Evidence of new visual field defects on autom

研究者

发起方

Astex Pharmaceuticals, Inc.

相似试验

进行中（未招募）

1 期

A Phase 1-2 Study of the Safety and Activity of ASTX029 in Patients with Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864

EUCTR2018-004568-72-FRAstex Pharmaceuticals, Inc.300

进行中（未招募）

1 期

TAK-788 (AP32788) in Patients With Non-Small Cell Lung Canceron-Small Cell Lung Cancer (NSCLSC)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-001271-68-ESMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited91

已完成

1 期

A Study of TAK-788 in Adults With Non-small Cell Lung CancerCarcinoma, Non-Small-Cell Lung

JPRN-jRCT2080224915Takeda Pharmaceutical Company Limited334

进行中（未招募）

1 期

TAK-788 (AP32788) in Patients With Non-Small Cell Lung Canceron-Small Cell Lung Cancer (NSCLSC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-001271-68-ITMILLENNIUM PHARMACEUTICALS, INC.91

进行中（未招募）

1 期

EUCTR2016-001271-68-GBMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited91